WallStreetZen

NASDAQ: ATRC
AtriCure Inc Stock Forecast, Predictions & Price Target

Analyst price target for ATRC

Based on 5 analysts offering 12 month price targets for AtriCure Inc.
Min Forecast
$65.00-9.41%
Avg Forecast
$91.20+27.11%
Max Forecast
$120.00+67.25%

Should I buy or sell ATRC stock?

Based on 6 analysts offering ratings for AtriCure Inc.
Buy
Strong Buy
2 analysts 33.33%
Buy
3 analysts 50%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

ATRC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Canaccord Genuity
Top 34%
67
Strong BuyMaintains$120.00+67.25%2021-08-05
Oppenheimer
Bottom 4%
4
HoldDowngradesN/AN/A2021-08-05
SVB Leerink
Top 20%
81
BuyMaintains$100.00+39.37%2021-08-05
Needham
Top 7%
94
BuyMaintains$90.00+25.44%2021-08-05
JP Morgan
Top 27%
74
Strong BuyMaintains$81.00+12.89%2021-05-14
Anonymous
SVB Leerink
BuyMaintains$65.00-9.41%2020-12-14

1 of 1

Forecast return on equity

Is ATRC forecast to generate an efficient return?
Company
-7.03%
Industry
18.2%
Market
1,975.18%
ATRC's Return on Equity is forecast to be low in 3 years (-7.03%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is ATRC forecast to generate an efficient return on assets?
Company
-3.86%
Industry
11.22%
Market
951.37%
ATRC is forecast to generate lower Return on Assets (-3.86%) than the US Medical Instruments & Supplies industry average (11.22%)
Forecast

ATRC earnings per share forecast

What is ATRC's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.23-3.91%
Avg 2 year Forecast
-$1.02-20.31%
Avg 3 year Forecast
-$0.59-53.91%

ATRC revenue forecast

What is ATRC's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$273.4M+12.47%
Avg 2 year Forecast
$324.8M+33.61%
Avg 3 year Forecast
$376.4M+54.8%
ATRC's revenue is forecast to grow at a rate of 15.6% per year, which is not exceptional
Forecast

ATRC revenue growth forecast

How is ATRC forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
15.6%
Industry
7.44%
Market
14.66%
ATRC's revenues are forecast to grow faster (15.6% per year) than the US Medical Instruments & Supplies industry average (7.44%)
Forecast
ATRC's revenues are forecast to grow faster (15.6% per year) than the US market average (14.66%)
Forecast

AtriCure Stock Forecast FAQ

Is AtriCure Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ATRC) stock is to Buy ATRC stock.

Out of 6 analysts, 2 (33.33%) are recommending ATRC as a Strong Buy, 3 (50%) are recommending ATRC as a Buy, 1 (16.67%) are recommending ATRC as a Hold, 0 (0%) are recommending ATRC as a Sell, and 0 (0%) are recommending ATRC as a Strong Sell.

What is ATRC's earnings growth forecast for 2021-2023?

(NASDAQ: ATRC) AtriCure's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 30.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 22.98%.

AtriCure's earnings in 2021 is -$56,679,000.On average, 2 Wall Street analysts forecast ATRC's earnings for 2021 to be $-56,435,412, with the lowest ATRC earnings forecast at $-57,353,061, and the highest ATRC earnings forecast at $-55,058,939. On average, 2 Wall Street analysts forecast ATRC's earnings for 2022 to be $-46,800,098, with the lowest ATRC earnings forecast at $-51,847,167, and the highest ATRC earnings forecast at $-41,753,029.

In 2023, ATRC is forecast to generate $-27,070,645 in earnings, with the lowest earnings forecast at $-32,576,539 and the highest earnings forecast at $-21,564,751.

What is ATRC's revenue growth forecast for 2021-2023?

(NASDAQ: ATRC) AtriCure's forecast annual revenue growth rate of 15.6% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.44%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 14.66%.

AtriCure's revenue in 2021 is $243,133,000.On average, 5 Wall Street analysts forecast ATRC's revenue for 2021 to be $12,546,280,384, with the lowest ATRC revenue forecast at $12,502,967,353, and the highest ATRC revenue forecast at $12,617,673,475. On average, 5 Wall Street analysts forecast ATRC's revenue for 2022 to be $14,904,638,263, with the lowest ATRC revenue forecast at $14,183,182,635, and the highest ATRC revenue forecast at $15,609,209,150.

In 2023, ATRC is forecast to generate $17,268,593,800 in revenue, with the lowest revenue forecast at $16,990,270,865 and the highest revenue forecast at $17,508,742,538.

What is ATRC's forecast return on assets (ROA) for 2021-2023?

(NASDAQ: ATRC) forecast ROA is -3.86%, which is lower than the forecast US Medical Instruments & Supplies industry average of 11.22%.

What is ATRC's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ATRC price target, the average ATRC price target is $91.20, with the highest ATRC stock price forecast at $120.00 and the lowest ATRC stock price forecast at $65.00.

On average, Wall Street analysts predict that AtriCure's share price could stay at $91.20 by Aug 5, 2022. The average AtriCure stock price prediction forecasts a potential downside of N/A from the current ATRC share price of $71.75.

What is ATRC's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: ATRC) AtriCure's current Earnings Per Share (EPS) is -$1.28. On average, analysts forecast that ATRC's EPS will be $-1.23 for 2021, with the lowest EPS forecast at $-1.25, and the highest EPS forecast at $-1.20. On average, analysts forecast that ATRC's EPS will be $-1.02 for 2022, with the lowest EPS forecast at $-1.13, and the highest EPS forecast at $-0.91. In 2023, ATRC's EPS is forecast to hit $-0.59 (min: $-0.71, max: $-0.47).

What is ATRC's forecast return on equity (ROE) for 2021-2023?

(NASDAQ: ATRC) forecast ROE is -7.03%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.